- Home
- CUE vs SEV Comparison
CUE vs SEV Comparison
Compare CUE & SEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | SEV |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | 46 |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 103.2M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | SEV |
|---|---|---|
| Price | $25.80 | $2.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $120.00 | N/A |
| AVG Volume (30 Days) | 71.2K | ★ 197.7K |
| Earning Date | 05-13-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17,757.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $1.29 |
| 52 Week High | $41.42 | $11.24 |
Technical Indicators
Market Signals| Indicator | CUE | SEV |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 41.52 |
| Support Level | $0.30 | $1.97 |
| Resistance Level | $32.60 | $3.26 |
| Average True Range (ATR) | 3.67 | 0.16 |
| MACD | -0.48 | 0.01 |
| Stochastic Oscillator | 53.77 | 41.72 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About SEV Aptera Motors Corp.
Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.